Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? (Q35434205)

8 August 2017

1 reference

title

Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? (English)

1 reference

8 August 2017

Matthew C Lucas

1

1 reference

8 August 2017

Seng-Lai Tan

series ordinal

2

1 reference

8 August 2017

publication date

1 January 2014

1 reference

Future Medicinal Chemistry

8 August 2017

published in

1 reference

8 August 2017

volume

6

1 reference

8 August 2017

issue

16

1 reference

8 August 2017

page(s)

1811-1827

1 reference

Kinase drug discovery--what's next in the field?

8 August 2017

cites work

1 reference

Targeting protein kinases for the development of anti-inflammatory drugs

21 January 2018

1 reference

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.

21 January 2018

1 reference

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

Spleen tyrosine kinases: biology, therapeutic targets and drugs

21 January 2018

1 reference

B-cell targeted therapies in human autoimmune diseases: an updated perspective

21 January 2018

1 reference

Activating and inhibitory FcgammaRs in autoimmune disorders.

21 January 2018

1 reference

Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives

21 January 2018

1 reference

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

21 January 2018

1 reference

Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis

21 January 2018

1 reference

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.

21 January 2018

1 reference

Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.

21 January 2018

1 reference

Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma

21 January 2018

1 reference

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

21 January 2018

1 reference

Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients.

21 January 2018

1 reference

A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis

21 January 2018

1 reference

Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE.

21 January 2018

1 reference

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

21 January 2018

1 reference

The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway.

21 January 2018

1 reference

The role of T cells in systemic lupus erythematosus: an update

21 January 2018

1 reference

Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells

21 January 2018

1 reference

Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling

21 January 2018

1 reference

Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.

21 January 2018

1 reference

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.

21 January 2018

1 reference

The 2010 patent landscape for spleen tyrosine kinase inhibitors

21 January 2018

1 reference

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

21 January 2018

1 reference

Rational design of highly selective spleen tyrosine kinase inhibitors

21 January 2018

1 reference

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

21 January 2018

1 reference

Discovery and development of spleen tyrosine kinase (SYK) inhibitors

21 January 2018

1 reference

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation

21 January 2018

1 reference

Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives

21 January 2018

1 reference

Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes

21 January 2018

1 reference

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors

21 January 2018

1 reference

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

21 January 2018

1 reference

Syk inhibitors with high potency in presence of blood

21 January 2018

1 reference

Idelalisib--a PI3Kδ inhibitor for B-cell cancers

21 January 2018

1 reference

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors

21 January 2018

1 reference

Highly potent aminopyridines as Syk kinase inhibitors

21 January 2018

1 reference

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.14.126

1 reference

8 August 2017

1 reference